FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)-Reference-Cited by-同舟云学术

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

Published:2009-07-28 Issue:1 Volume:119 Page:95-104
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Polyzos Aristides,Malamos Nikolaos,Boukovinas Ioannis,Adamou Adamos,Ziras Nikolaos,Kalbakis Kostas,Kakolyris Stylianos,Syrigos Kostas,Papakotoulas Pavlos,Kouroussis Charalambos,Karvounis Nikolaos,Vamvakas Lambros,Christophyllakis Charalambos,Athanasiadis Athanasios,Varthalitis Ioannis,Georgoulias Vassilis,Mavroudis Dimitris

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-009-0468-0.pdf

Reference15 articles.

1. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 365:1687–1717

2. Ravdin PM, Burris HA, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879–2885

3. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983

4. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results of NSABP B-28. J Clin Oncol 21:3686–3696

5. Martin M, Rodriquez-Lescure A, Ruiz A et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805–814

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer;British Journal of Cancer;2022-02-10

2. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial;Clinical Breast Cancer;2020-12

3. Taxanes for adjuvant treatment of early breast cancer;Cochrane Database of Systematic Reviews;2019-09-02

4. Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel;European Journal of Pharmaceutics and Biopharmaceutics;2017-05

5. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study;British Journal of Cancer;2016-03-31